Sage Therapeutics (SAGE) PT Lowered to $48 at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts SAGE Hot Sheet
Price: $8.68 --0%
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
Guggenheim analyst Yatin Suneja lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $48.00 (from $55.00) while maintaining a Buy rating.
You May Also Be Interested In
- Dynatrace Inc. (DT) PT Lowered to $60 at DA Davidson
- Cinemark Holdings (CNK) PT Raised to $45 at StoneX
- Viridian Therapeutic (VRDN) PT Raised to $43 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
